Grufity logo
Grufity logo
DCTH

DCTH - Delcath Systems, Inc. Stock Price, Fair Value and News

$12.22+0.18 (+1.50%)
Market Closed as of 31 Jul 2026, 04:00 pm ET

61/100

DCTH

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

61/100

DCTH

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

DCTH Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

DCTH Price Action

Last 30 days

-5.3%

Last 90 days

13.2%

Trailing 12 Months

13.7%

DCTH RSI Chart

DCTH Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

DCTH Valuation

Market Cap

421.9M

Price/Earnings (Trailing)

751.97

Price/Sales (Trailing)

4.66

EV/EBITDA

235.12

Price/Free Cashflow

21.98

DCTH Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

DCTH Fundamentals

DCTH Revenue

Revenue (TTM)

90.4M

Rev. Growth (Yr)

26.33%

Rev. Growth (Qtr)

20.58%

DCTH Earnings

Earnings (TTM)

561.0K

Earnings Growth (Yr)

-200.09%

Earnings Growth (Qtr)

43.57%

DCTH Profitability

Operating Margin

85.97%

EBT Margin

1.48%

Return on Equity

0.5%

Return on Assets

0.45%

Free Cashflow Yield

4.55%

DCTH Investor Care

Buy Backs (1Y)

0.35%

Diluted EPS (TTM)

0.01

Revenue & Growth

How Delcath Systems, Inc. generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
202690.4M---
202553.9M70.2M79.6M85.2M
20244.6M11.9M22.6M37.2M
20232.9M2.6M2.2M2.1M
20223.2M3.2M3.3M2.7M
2021---3.6M
20182.7M2.9M3.1M-
20172.4M2.4M2.7M2.7M
20161.7M1.7M1.8M2.0M
20151.2M1.4M1.6M1.7M
2014720.0K971.0K1.1M1.1M
2013457.3K568.5K679.8K791.0K
2012---346.0K
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Delcath Systems, Inc.

DCTH
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
 CEO
 WEBSITEdelcath.com
 SECTORHealthcare
 INDUSTRYMedical Devices
 EMPLOYEES52

Delcath Systems, Inc. Frequently Asked Questions

DCTH is the stock ticker symbol of Delcath Systems, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Jul 31 2026, market cap of Delcath Systems, Inc. is 421.85 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Jul 31 2026, DCTH's PE ratio (Price to Earnings) is 751.97 and Price to Sales (PS) ratio is 4.66. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DCTH PE ratio will change depending on the future growth rate expectations of investors.